-
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
01 May 2024 20:18 GMT
… Officer (CStO) of Astellas
"At Astellas, we have a … of Interest | Astellas Pharma Inc.
About Astellas
Astellas Pharma Inc. is … continuous creation of new drugs to address diseases with … Xyphos Biosciences, Inc., an Astellas Company
Xyphos Biosciences, Inc., …
-
Astellas adds to ‘off-the-shelf’ cell therapy capabilities with Poseida deal
01 May 2024 14:18 GMT
… therapies for solid tumors. Astellas will pay Poseida $50 million … some of its top-selling drugs. The company has since … for making cell therapies.
Astellas has also shown interest in … expanded deal with Poseida gives Astellas more allogeneic prospects. “The …
-
Astellas Pharma Inc. (ALPMF) Q4 2023 Earnings Call Transcript
27 Apr 2024 02:56 GMT
… 39;m Naoki Okamura from Astellas Pharma Inc. Thank you … knowledge and experiences through drug discovery in mitochondria-related … areas and new drug development for rare diseases. … is to generate promising new drugs continuously. To accelerate the …
-
Ironwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week® 2024
01 May 2024 11:41 GMT
… U.S. Food and Drug Administration (FDA) and … head of research and drug development at Ironwood Pharmaceuticals … Ironwood's partner, Astellas, markets linaclotide under the … candidates, including abbreviated new drug application litigation; challenges from …
-
CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024
01 May 2024 12:00 GMT
… multiple treatment modalities including antibody-drug conjugates (“ADCs”), T-cell engagers … leaders in oncology, including Amgen, Astellas, Bristol Myers Squibb, Regeneron and …
-
Regulatory actions for April 30, 2024
30 Apr 2024 18:10 GMT
Regulatory snapshots, including drug submissions and approvals, clinical trial … and designations in Asia-Pacific: Astellas, Apollomics, Avistone, Hutchmed, Lantern, Onconic …
-
Japan's Ono Pharma says $2.4 billion Deciphera purchase 'first step' for global expansion
30 Apr 2024 08:05 GMT
… and Astellas Pharma which have spent big recently to replenish their drug … globally for its blockbuster cancer drug Opdivo, which is sold … Bristol-Myers Squibb. The drug expected to lose patent protection … Deciphera's oral drug Qinlock to treat a type …
-
4D Molecular Therapeutics: Catalysts With Pioneering Gene Therapy With Directed Evolution
29 Apr 2024 13:15 GMT
… 5) undisclosed drug with a vector licensed to Astellas for unrevealed Rare … ] program presents an early-development drug candidate for Amyotrophic Lateral Sclerosis … WORLDSymposium in February 2024. The drug demonstrated clinical symptom improvements, robust …
-
Pfizer Highlights Progress in Accelerating Breakthrough Cancer Medicines at ASCO 2024 Annual Meeting
29 Apr 2024 11:03 GMT
… modalities, including small molecules, antibody-drug conjugates (ADCs) and bispecific …
Strickler et al
*Pfizer and Astellas have a clinical collaboration agreement … angles, including small molecules, antibody-drug conjugates (ADCs), and bispecific …
-
Regulatory tracker: FDA offers Pfizer's Tivdak full nod in cervical cancer
03 Jan 2024 17:45 GMT
… 39;s Cancer Drugs Fund (CDF).
The drug has already reached … treatment of gastric cancer, Astellas’ head of immuno-oncology … to placebo and chemotherapy.
Astellas has submitted approval bids … among previously treated patients.
Astellas said Japan's …